Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 2024-A01041-46 | Other Identifier | ID RBC |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Objectives: The discovery of aneurysmal or ectatic lesions of the coronary arteries during coronary angiography or coronary CT angiography poses a triple challenge in terms of aetiology, treatment and prognosis. The aim of this study, based on coronary angiograms performed over a 10-year period at the Centre Hospitalier de Versailles, was to determine which antithrombotic treatment was routinely prescribed to patients with ACC or AEC, the evolution of this long-term treatment, and to analyse the association between the presence/absence of anticoagulant treatment and the rates of ischaemic cardiovascular events and haemorrhagic complications.
Materials and methods: This is a non-interventional, observational, single-centre study conducted at the Versailles Hospital Centre from 2013 to 2023, based on the department's coronary angiography registry. The study included adult patients, living or deceased, hospitalised in the cardiology department who underwent coronary angiography between 1 January 2013 and 31 December 2023, which showed the presence of aneurysms or ectatic atheroma with bi- or tri-vessel coronary involvement.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| aneurysmal or ectatic lesions of the coronary arteries | This is a non-interventional, observational, single-centre study conducted at the Centre Hospitalier de Versailles from 2013 to 2023, based on the department's coronary angiography registry. The study included adult patients, both living and deceased, who were hospitalised in the cardiology department and underwent coronary angiography between 1 January 2013 and 31 December 2023, which showed the presence of aneurysms or ectatic atheroma with bi- or tri-vessel coronary involvement. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Anticoagulant Treatment | Other | Follow-up of patients with coronary aneurysms and treatments introduced (anticoagulants and/or antiplatelet agents) to monitor the onset of ischaemic or haemorrhagic complications between 2013 and 2023. |
| Measure | Description | Time Frame |
|---|---|---|
| The nature of the antithrombotic treatment prescribed between the initial hospital discharge and the follow-up date | The nature of the antithrombotic treatment prescribed between the initial hospital discharge and the follow-up date (anti-platelet agents alone, single or dual therapy, anticoagulant alone, anti-platelet agent-anticoagulant combinations). | Treatment on discharge from hospital and follow-up treatment beween 2013 and 2023 |
| The nature of antithrombotic treatments | The nature of antithrombotic treatments | Discharge from hospital (day 1) |
| Measure | Description | Time Frame |
|---|---|---|
| The occurrence of ischaemic cardiovascular events (cardiovascular death, myocardial infarction, unscheduled coronary revascularisation) | The occurrence of ischaemic cardiovascular events (cardiovascular death, myocardial infarction, unscheduled coronary revascularisation) | The follow-up period between 2013 and 2023 |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
A patient with aneurysmal or ectatic coronary disease with bi- or tri-truncular involvement on coronary angiography.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Franck ASSAYAG | Versailles Hospital | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Centre Hospitalier de Versailles | Le Chesnay | 78150 | France |
Not provided
Not provided
Not provided
Not provided
|
| The occurrence of haemorrhagic events of any kind |
The occurrence of haemorrhagic events of any kind |
| The follow-up period between 2013 and 2025 |